Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
$ 18.725 0.275 (1.49%) Market Cap: 21.07 Bil Enterprise Value: 37.43 Bil PE Ratio: 0 PB Ratio: 3.31 GF Score: 59/100

Q4 2023 Teva Pharmaceutical Industries Ltd Earnings Call Transcript

Jan 31, 2024 / 01:00PM GMT
Release Date Price: $12.1 (+3.15%)
Operator

Hello, and welcome to the Fourth Quarter and Full Year 2023 Teva Pharmaceutical Industries Earnings Conference Call. My name is Alex. I'll be coordinating the call today.

(Operator Instructions)

I'll now hand it over to your host, Ran Meir, Head of Investor Relations. Please go ahead.

Ran Meir

Thank you, Alex. Thank you, everyone, for joining us today. We hope you had an opportunity to review our press release, which was issued earlier this morning. A copy of this press release as well as a copy of the slides being presented on this call can be found on our website at tevapharm.com. Please review our forward-looking statements on Slide #2. Additional information regarding these statements and our non-GAAP financial measures is available on our earnings release and in our SEC Forms 10-K and 10-Q.

To begin today's call, Richard Francis, Teva's CEO, will provide an overview of Teva's 2023 full year results and business performance, recent events and our focus and priorities going forward. Then Dr. Eric Hughes, our Head of R&D and Chief

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot